2852 Cimetidine A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. 51481-61-9 2756 C10H16N6S 252.115710 White powder. 142°C 9380 mg/L (at 25°C) Oral, rapid 60-70% Cimetidine binds to an H₂-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity. Hepatic Route of Elimination: The principal route of excretion of cimetidine is the urine. Half Life: 2 hours 3, not classifiable as to its carcinogenicity to humans. (L135) For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion. Symptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat. The usual measures to remove unabsorbed material from the gastrointestinal tract, clinical monitoring and supportive therapy should be employed. (L1712) 2009-07-21T20:27:02Z 2026-03-31T17:03:14Z Cimetidine C06952 3699 Cimetidine DB00501 true C\N=C(\NCCSCC1=C(C)NC=N1)NC#N C10H16N6S InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14) AQIXAKUUQRKLND-UHFFFAOYSA-N 252.339 252.115715232 Exogenous Solid 0.4 HMDB14644 CHEMBL30 2654 <p>Saburo Uchikuga, Tomoyasu Tashiro, Yasuko Osawa, &#8220;Process for preparing the H.sub.2 -receptor antagonist cimetidine.&#8221; U.S. Patent US4413129, issued March, 1972.</p> CHEM002212 DTXSID4020329 NS00008665 (Z)-N-cyano-N''-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine